This requirement is to engage a laboratory to perform coagulopathy biomarker assays and send the results to NCI for analyses to be completed by NCI statisticians and the study team. POP 03/01/2021 -…
Ended Awarded Last action
- Contract number
- 75N91021F00056
- Awardee
-
Quest Diagnostics Incorporated UEI UC5SPMUJF8V3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $870,035
Award facts
- Contract value 77% obligated
-
- $870,034.80 Current, with exercised options
- $1,123,780.80 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Time and Materials
- Place of performance
- Secaucus, NJ 07094, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $155,897 | |
| Exercise an Option | $152,248 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $155,897 | |
| Funding Only Action | $30,902 | |
| Original award | $375,092 |
About this award
Quest Diagnostics Incorporated will provide laboratory testing and analysis services to the National Cancer Institute (NCI), an institute of the National Institutes of Health within the Department of Health and Human Services, under a $1.1 million time-and-materials delivery order awarded against the Medical Laboratory Testing and Analysis Services Federal Supply Schedule. Specifically, Quest Diagnostics will perform coagulopathy biomarker assays and send the results to NCI to support analyses for the NCI COVID-19 in Cancer Patient Study being conducted through February 2024. The assays will be performed at Quest Diagnostics' laboratory in Secaucus, New Jersey. No subcontractors or set-aside designations were identified.
Description
This requirement is to engage a laboratory to perform coagulopathy biomarker assays and send the results to NCI for analyses to be completed by NCI statisticians and the study team. POP 03/01/2021 - 02/28/2022.
Quick answers
Who was awarded contract 75N91021F00056?
75N91021F00056 was awarded to Quest Diagnostics Incorporated by National Cancer Institute (National Institutes of Health) on March 1, 2021.
How much is contract 75N91021F00056 worth?
The government has obligated $870,035 on 75N91021F00056. Its potential value, with all options, is $1,123,781.
Is contract 75N91021F00056 an order under another contract?
Yes. 75N91021F00056 is a delivery order under V797D70090, a federal supply schedule, on Medical Laboratory Testing and Analysis Services (FSS-621-II).
Was contract 75N91021F00056 competed?
The extent of competition for 75N91021F00056 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award